Document:

Amendment to Development Agreement with James A. Youssef

 Exhibit 10.33 
  
 AMENDMENT TO DEVELOPMENT AGREEMENT 
  
 This Amendment to Development Agreement is made and entered into as
of the 24th day of May, 2006, by and between Amedica Corp., a Delaware Corporation (“Amedica”), and Jim A.
Youssef, M.D. (“Youssef”). 
  
  
 RECITALS 
  
 A. By date of May 8, 2004, the parties entered into a Development Agreement (the “Agreement”) regarding a development of devices. 
  
 B. The parties desire to amend the Agreement to define the specific devices covered by the Agreement and to amend and clarify the amount of Youssef’s
compensation thereunder. 
  
 NOW, THEREFORE, in consideration of
the foregoing and the mutual covenants and agreements hereinafter set forth, and other valuable consideration, the parties agree as follows: 
  
 1. All references to “Device(s)” through the Agreement refer to, and are limited to: (i) the [******************] made from
[************], and (ii) the [******************] made of [**************]. 
  
 2. The first sentence in paragraph 4(a) is amended and restated as follows: 
  
 Youssef shall, in the form of royalty or similar payments, receive [**********] of the net
after-tax profit. 
  
 The remainder of subparagraph 4(a)
shall continue in full force and effect. 
  
 3. Paragraph 4(b) is
eliminated and superceded. 
  
 4. All references or implications,
if any, in the Agreement to any required sharing by Youssef of royalties with any collaborators or other third parties are terminated and eliminated from the Agreement. 
  
 5. If any remaining provision of the Agreement, after giving effect to the Amendments provided above, conflicts with any of
these Amendments, that conflicting provision shall be interpreted and applied consistent with these Amendments. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 6. Except as otherwise specifically provided herein all other provisions of the Agreement shall continue
in full force and effect. 
  
 Dated as of the day
and year first above mentioned. 
  

							
	 ADDRESS:
	 	AMEDICA:	 	
			
	 615 Arapeen Drive, Suite 302
	 	Amedica Corp.	 	
	 Salt Lake City, UT 84108
	 	a Delaware Corporation	 	
				
		 	By	 	 /s/ Eugene B. Jones
	 	
				
		 	Its	 	Vice President - Finance and CFO	 	
			
		 	YOUSSEF:	 	
			
		 	 /s/ Jim A. Youssef
	 	
	 [********************]
	 	Jim A. Youssef, M.D.	 	
	 [********************]
	 		 		 	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended.Development Agreement with Jean-Jacques Abitol

 Exhibit 10.34 
  
 EXECUTION COPY 
  
 DEVELOPMENT AGREEMENT 
  
 This Development Agreement (this “Agreement”) is made and entered into as of the 16th day of February 2005 (the “Effective Date”), by
and between AMEDICA CORP., a Delaware corporation (“Amedica”), and Jean-Jacques Abitbol, M.D. (“Abitbol”). 
  
  
 RECITALS: 
  
 A. Amedica is in the business of designing, developing and selling various products and applications for medical and
biomedical uses and from various materials, including the use of advanced ceramic materials. 
  
 B. Amedica desires to continue to encourage, through collaboration among two or more professionals (“Collaborators”), the conceiving, development, testing, marketing and dealing with novel devices for
implant in or use with hip and knee reconstructive medical and surgical procedures (“Devices”), whether manufactured from ceramic materials or other materials. 
  
 C. Abitbol is an orthopedic surgeon having knowledge and expertise relating to the spine. 
  
 D. The parties desire to enter into arrangements between the parties to
assist in the future development, approval, trial and clinical use of Devices. 
  
 NOW, THEREFORE, for and in consideration of the mutual promises and covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
agree and represent as follows: 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 1. Definitions. For purposes of this Agreement, the following terms shall have the
following definitions: 
  
 a. “Development Services”
means the development and related services as requested by Amedica relating to the conceptualization, development, testing, approval and related matters involving the Devices more fully described in Section 2, below. 
  
 b. “Devices” means all ideas, discoveries, creations, improvements,
know-how, inventions, designs, developments, apparatus, techniques, methods, processes, and materials, whether or not patentable, including all rights to obtain, perfect or enforce any proprietary interests therein, in the Field of Interest, which
Abitbol, whether alone or in concert with others, may conceive, reduce to practice or develop during the Term (or, if based on or related to any confidential or proprietary information of Amedica, within [***********] after the termination of this
Agreement), alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of Amedica, or otherwise. These Devices include but are not limited to those items more
fully identified on Schedule A attached hereto. 
  
 c. “Field
of Interest” means the development, testing and commercializing of biomedical or surgical devices, covered by current Amedica patent applications and further Amedica developments, and utilizing ceramic materials, intended for use in diagnosing,
preventing or treating diseases or conditions affecting the hip or knee or related structure or tissues or any applications thereof. Amedica may expand or otherwise change the definition of its Field of Interest at any time, as long as this
expansion continues to be related to ceramic materials, which new definition will be binding upon Abitbol ten (10) days after written notice to Abitbol thereof. 
  

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 d. “Collaborators” refer to the list of professionals more fully identified on Schedule B
attached hereto. 
  
 2. Cooperative Development
Arrangements. The parties intend that Abitbol, in collaboration and cooperation with the Collaborators shall diligently perform the Development Services and provide reasonable input and expertise from Abitbol and each Collaborator hereunder.
The Development Services shall include, without limitation, the following 
  
 a. Examining and reviewing the characteristics of the Devices and the nature of the materials with which the Devices are constructed. 
  
 b. Providing expertise in ideas and testing pertaining to the Devices, and coordination with other Amedica personnel and
third parties related to such testing, as requested by Amedica. 
  
 c. Providing guidance and assistance in the clinical details of the Devices. 
  
 d. Using commercially reasonable efforts to generate interest in the Devices from companies who may seek to enter into a transaction with Amedica relating to the Devices. 
  
 e. Assisting in the filing of provisional patents and other patents
pertaining to the Devices as determined by Amedica. 
  
 f.
Assisting in applying for or otherwise seeking regulatory approval for the Devices or surgical processes for their implantation or other use. 
  
 3. Term and Termination. 
  
 a. The term (the “Term”) of this Agreement shall commence as of the Effective Date and shall continue until the later of: (i) ten
(10) years from the date hereof; or (ii) the expiration of patent rights on the Devices, unless earlier terminated as provided hereunder. 
  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. Either party has the right to terminate this Agreement at any time upon thirty (30) days’
prior written notice to the other. 
  
 c. Upon the death or
termination of another Collaborator, not resulting in the termination of the Agreement by Abitbol and any other Collaborator, this Agreement shall continue (subject to Subsection 3(b) above) as to Abitbol and remaining Collaborator(s); provided,
that the remaining parties to this Agreement shall, as soon as reasonably possible, negotiate in good faith any modifications to Abitbol’s duties as may be appropriate under the circumstances. 
  
 4. Facilities. To the extent necessary, Amedica shall provide
Abitbol office space, equipment, telephone, secretarial help and all other equipment and related services necessary for the performance of the Development Services hereunder. 
  
 5. Exclusivity. Amedica acknowledges that Abitbol has other professional business and investment dealings in
addition to his responsibilities under this Agreement and that Abitbol will not be required to devote his time exclusively to his responsibilities hereunder. Notwithstanding any provision herein to the contrary, Abitbol agrees that during the Term,
Amedica shall have the exclusive right to the Devices. 
  
 6.
Confidentiality. 
  
 a. Both during the Term and
following termination of this Agreement for any reason, except as necessary for the performance of the Development Services hereunder, Abitbol shall not, at any time or in any manner, directly or indirectly, use, divulge, disclose or communicate to
any third-person or entity any information that was disclosed to or developed by Abitbol during the course of performing the Development Services and which is not generally available to the public, including, without limiting the generality of the
foregoing: information 

  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
regarding matters affecting or relating to Amedica’s business or its Devices; the nature of Amedica’s properties or products, whether developed or
under development; the identity of Amedica’s customers; prices which Amedica obtains or has obtained with respect to its products or services; information as to Amedica’s discussions, negotiations and/or dealings with actual or potential
third-party buyers, investors, licensees or co-venturers; Amedica’s costs, overhead or profit margin; or Amedica’s operational methods or its business plans and processes. All material as such will be labeled “confidential”.

  
 b. Records. Promptly following termination of this Agreement,
Abitbol shall deliver to Amedica any and all property of Amedica which may be in his possession including products, materials, memoranda, notes, records, reports, writings, drawings, diskettes, models and other materials or other documents or
photocopies of the same in any tangible form whatsoever constituting confidential or proprietary information of Amedica, and any of the foregoing in intangible form. 
  
 7. Covenant Not to Compete. 
  
 a. Certain Acknowledgments and Agreements. Abitbol recognizes and acknowledges the competitive and proprietary nature
of Amedica’s business operations. Abitbol acknowledges and agrees that a business will be deemed competitive with Amedica if it engages in a line of business in which it develops, manufactures or sells any products provided or offered by
Amedica or any similar products, or products fulfilling the same function, in the Field of Interest (such business to be referred to as a “Competitive Business”). 
  
 b. Abitbol agrees that during the Term and for an additional [*********] after termination of this Agreement (which
period shall be tolled during the period of any violation or breach of any of the provisions hereof and for a period of [*********] thereafter), whether such termination is voluntary or involuntary, Abitbol shall not: 
  
 (i) for his benefit, or on behalf of any other person or
entity, directly or indirectly, as principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or control, or be concerned, connected or employed by, or otherwise associate in any manner with,
engage in or have a financial interest in any Competitive Business anywhere in the continental United States of America (the “Restricted Territory”), except that nothing contained herein shall preclude Abitbol from purchasing or owning
securities of any such business if such securities are publicly traded, and provided that his holdings do not exceed one percent (1%) of the issued and outstanding securities of any class of securities of such business; or 
  

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (ii) either individually or on behalf of or through any third party, solicit, divert or
appropriate or attempt to solicit, divert or appropriate, any known customers or patrons of Amedica; or 
  
 (iii) either individually or on behalf of or through any third party, directly or indirectly, solicit, entice or persuade or attempt to
solicit, entice or persuade any other employees of or consultants to Amedica or any present or future parent, subsidiary or affiliate of Amedica to leave the services of Amedica or any such parent, subsidiary or affiliate for any reason. 

 
 c. Reasonableness of Restrictions. Abitbol further recognizes and
acknowledges that: (i) the restrictions in this Section 7 are reasonable in relation to the skills which represent his principal salable asset both to Amedica and to any prospective employers, and (ii) the geographical scope of the
provisions of this Section 7 is reasonable, legitimate and 

  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
fair to Abitbol in light of Amedica’s need to market its services and sell its products worldwide in order to have a sufficient customer base to make
Amedica’s business profitable and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Abitbol is qualified to earn his livelihood. 
  
 d. Survival of Acknowledgments and Agreements. The acknowledgments
this agreements set forth in this Section 7 shall survive the expiration or termination of this Agreement and the termination of Abitbol’s employment, or consulting arrangements, with Amedica for any reason. 
  
 8. Ownership of Ideas, Copyrights and Patents. 
  
 a. Disclosure of Devices. Abitbol agrees that he will promptly
disclose all Devices to Amedica and that he will not publish any Devices, or any information with regard thereto, without the prior written consent of Amedica. 
  

b. Property of Amedica. Amedica shall have the sole and exclusive right, even as to Abitbol, to prepare, file, prosecute, obtain and maintain
any and all patents and patent applications claiming any Devices. All Devices shall be the sole and exclusive property of Amedica and, subject to payment pursuant to the provisions of Section 3 hereof, Abitbol hereby assigns to Amedica all of
his right, title and interest in and to all of the Devices. Abitbol further agrees to use his best efforts to ensure that no Devices will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or
slander against or violate any other rights of any person, firm or corporation. 
  
 c. Prior Rights. Abitbol has attached hereto as Schedule C (i) a list of all proprietary concepts and inventions in which he has any right, title, or interest as of the date of his execution of this
Agreement (“Prior Rights”), and (ii) a list of all Prior Rights made, 

  

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
conceived, or developed, in whole or in part, by Abitbol prior to the date of his execution of this Agreement, and Abitbol represents that Schedule C is a
complete and accurate list of all Prior rights. 
  
 d.
Cooperation. Abitbol hereby agrees to willfully cooperate with Amedica, its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect Amedica’s rights in and to any Devices,
including, but not limited to, performing all acts deemed necessary or desirable by Amedica (both during the Term and for a period of [***********] after expiration of this Agreement) and joining in any proceeding to obtain letters patent,
copyrights, trademarks or other legal rights of the United States of America and of any and all other countries to Devices; provided, that, Amedica will bear the expense of all such proceedings. Abitbol hereby agrees that any patent or other legal
right covering any Device issued to Abitbol personally, shall be assigned by Abitbol to Amedica without charge by Abitbol, except as specifically provided under Section 3 hereof. 
  
 e. Works Made For Hire. Without limiting the foregoing, Abitbol further acknowledges that all original works of
authorship made by such Abitbol, within the Field of Interest, whether alone or jointly with others in the performance of the Development Services and which are protectable by copyright are “works made for hire” within the meaning of the
United States Copyright Act, 17 U.S.C. § 101, as amended, the copyright of which shall be owned solely, completely and exclusively by Amedica. If any Device is considered to be work not included in the categories of work covered by the United
States Copyright Act, 17 U.S.C. § 101, as amended, such work shall be owned solely by, or hereby assigned or transferred completely and exclusively to, Amedica. 
  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 9. Representations and Warranties Regarding Prior Work and Legal Obligations. 

 
 a. Abitbol hereby represents and warrants that he has no commitments or
obligations with any prior employer or any other person or entity that, would restrict his ability to perform the Development Services, or is inconsistent with this Agreement and Abitbol hereby agrees to indemnify and hold Amedica harmless against
loss, damage, liability or expense arising from any claim based upon circumstances alleged to be inconsistent with such representation and warranty. 
  
 b. Abitbol represents that he has been advised by Amedica that at no time should he divulge to, or use for the benefit of, Amedica any trade secret or
confidential or proprietary information of any previous employer. Abitbol acknowledges that he has not divulged or used any such information for the benefit of Amedica. 
  
 c. Abitbol represents that he has not and will not misappropriate any invention that he played any part in creating while
working for any former employer. 
  
 d. Abitbol acknowledges that
Amedica is basing important business decisions on these representations, and affirms that all of the statements included herein are true. 
  
 10. Equitable Remedies. Abitbol acknowledges that the breach of the provisions of Sections 6, 7, 8 and 9 above shall constitute irreparable
damage to Amedica and, accordingly, Amedica may, in addition to all other available remedies under law and equity, obtain injunctive relief upon an alleged violation of such Sections pending resolution on the merits of any claims raised by Amedica
hereunder. 
  
 11. Stock Option Arrangements. As
further consideration hereunder, the parties agree in good faith to negotiate an agreement granting Abitbol certain rights to obtain options for the purchase of Amedica stock. The nature, amount and terms of such options shall be agreed upon by the
parties in good-faith as soon as reasonably possible. 
  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 12. Development Agreement Only. This Agreement constitutes a development agreement only.
Nothing herein is intended, nor shall it be construed, to create any employer/ employee arrangement, partnership arrangement or other relationship between or among the parties except as expressly provided herein; and nothing herein is intended to
grant to either party any right or interest in or to the assets, business or interests of the other party, nor the right to bind the other party except as expressly herein provided. 
  
 13. Compliance with Laws and Regulations. The parties, at all times, shall interpret and apply the provisions
of this Agreement strictly in accordance with all applicable laws and regulations, including, but not limited to, the so-called Stark federal anti-referral law and all Medicare and Medicaid laws and regulations. 
  
 If any provision of this Agreement is found, by any applicable court or
government agency, to be in conflict with any applicable law or regulation, the provisions of such law or regulation shall govern; and the interpretation and operation under this Agreement shall be modified accordingly. 
  
 14. Indemnification by Amedica. 
  
 a. Amedica will indemnify and hold Abitbol harmless from any and all claims,
costs, judgments and expenses involving (i) any claim that any Device infringes or interferes with any patent or other proprietary claim of any third-party, and (ii) to the extent claimed or proven to be solely due to Device design or
manufacturing defect (including reasonable attorneys’ fees) of whatever sort based on claims of product design or manufacturing defects whether sounding in negligence, strict liability at law, contract or statutory violation, and (iii) any
breach by Amedica of any provision of this Agreement. 
  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. Any indemnification provided by Amedica hereunder shall not apply to any claim insofar as that claim
(i) relates to a professional medical liability or malpractice claim brought against Abitbol for professional acts or omissions in connection with the medical care or treatment associated with a Device; (ii) arises from any breach by
Abitbol of any provision of this Agreements; or (iii) arises from any knowing submission by Abitbol of false data to Amedica or from any other intentional wrongdoing by Abitbol. 
  
 c. Promptly upon Abitbol’s receipt of information concerning the commencement of any third-party claim, demand, action,
suit or proceeding (collectively, “Action”) which is the subject of indemnification hereunder, Abitbol shall notify Amedica in writing of the commencement of the Action. Any failure to provide such prompt notice shall relieve Amedica of
its indemnification obligations to the extent Amedica has been materially prejudiced by such failure. Amedica may select counsel at its own expense and control the defense of such indemnity claim; and Abitbol may participate jointly with Amedica in
such defense, at Abitbol’s expense, in which event the parties shall reasonably cooperate with each other subject, however, to Amedica’s ultimate control of the defense. With respect to any Action relating solely to the payment of money
damages, Amedica shall have the sole right to defend, settle, or otherwise dispose of such claim on such terms as Amedica, in its sole discretion, shall deem appropriate; provided, that Amedica shall provide reasonable evidence of its ability to pay
any damages claimed. If the Action involves any claim in which Abitbol would become subject to injunctive relief or to other equitable relief, or Abitbol’s business would be adversely affected in any manner, Amedica shall settle that claim only
upon the written consent of Abitbol, which shall not be unreasonably withheld. 
  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 15. Indemnification by Abitbol. Except to the extent that any such claims arise through the
wrongful act or neglect of Amedica, Abitbol will indemnify and hold Amedica harmless from any and all claims, costs, judgments and expenses arising from any breach by Abitbol of any provision of this Agreement. 
  
 16. General. 
  
 a. Notices. All notices required or permitted to be given to a party
hereunder shall be mailed by certified mail or registered mail, postage prepaid, to that party’s address set forth on the signature page of this Agreement (or to such other address specified in writing). 
  
 b. Default. If either party defaults in any of the covenants or
provisions herein, the defaulting party shall pay all costs and attorneys’ fees incurred by the other party in enforcing its rights arising hereunder. 
  
 c. Governing Law and Venue. This Agreement shall be interpreted, performed and enforced according to the laws of Utah. Venue for any action hereof
shall lie with the Third Judicial District Court of the State of Utah for the United States District Court for the District of Utah, Central Division. 
  
 d. Unenforceable Provision. If any provision of this Agreement is deemed unenforceable by any court of competent jurisdiction, the remaining
provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be over broad as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision
enforceable according to applicable law and shall be enforced as amended. 
  

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. Assignment. Amedica may assign its rights and obligations hereunder to any person or entity
that succeeds to all or substantially all of Amedica’s business or that aspect of Amedica’s business in which Abitbol is principally involved. Abitbol’s rights and obligations under this Agreement may not be assigned by that Abitbol
without the prior written consent of Amedica. 
  
 f.
Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto.
Nothing in this Agreement shall be construed to create any rights or obligations except between the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement, other than any future parent, subsidiary or
affiliate of Amedica. 
  
 g. Entire Agreement. This
Agreement embodies the entire agreement and understanding between and among the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No
statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 
  
 h. Modifications and Amendments. The terms and provisions of this
Agreement may be modified or amended only by written agreement executed by the parties hereto. 
  
 i. Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such
terms or provisions. No such waiver or consent shall be 

  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such
waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 
  
 j. Construction. The parties have participated equally in the formation of this Agreement and the language of this
Agreement will not be presumptively construed against either party. 
  
 k. Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 
  
 l. Section Numbers and Headings. The
Section and Subsection headings and numbers used herein are for purposes of convenience and shall not be considered in the interpretation of this Agreement. 
  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF this 16th day of February 2005. 
  

					
		 		 	AMEDICA
			
	ADDRESS:	 		 	AMEDICA CORP.
		 		 	A DELAWARE CORPORATION
	Amedica Corporation	 		 	
	615 Arapeen Drive, Suite 302	 		 	 /s/ Eugene B. Jones

	Salt Lake City, UT 84108	 		 	Eugene B. Jones
		 		 	Vice President, Finance & CFO
		 		 	
		 		 	ABITBOL
	ADDRESS:	 		 	
			
	Jean-Jacques Abitbol M.D.	 		 	
	[********************]	 		 	
	[********************]	 		 	
	[********************]	 		 	 /s/ Jean-Jacques Abitbol

		 		 	Jean-Jacques Abitbol, M.D.

  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

  
 SCHEDULE A

  
 Devices 
  
 The Devices consist of the following, [**********************************]:

  

	1.	 	[*********] 

  

	2.	 	[*********] 

  

	3.	 	[*********] 

  

	4.	 	[*********] 

  

	5.	 	[*********] 

  

	6.	 	[*********] 

  

	7.	 	[*********] 

  

	8.	 	[*********] 

  

	9.	 	[*********] 

  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

  
 SCHEDULE B

  
 List of Collaborators 
  
 [**************************] 
  
 [1] [*********] 
  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE C 
  
 Prior Rights 
  

 18 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]